Phoenix Biotech Acquisition Corp.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PBAX research report →
Price Chart
About the company
Phoenix Biotech Acquisition Corp. currently lacks substantial business operations. The company's primary objective is to complete a strategic business combination, such as a merger, asset acquisition, share exchange, or other form of reorganization, with one or more suitable enterprises.
- CEO
- Christopher B. Ehrlich
- IPO
- 2021
- HQ
- Oakland, CA, US
Get TickerSpark's AI analysis on PBAX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $36.47M
- P/E
- -0.27
- PEG
- -0.01
- P/S
- 0.00
- P/B
- -8.09
- EV/EBITDA
- -14.62
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 766.14%
- ROIC
- 79.91%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-18,463,149
- Net Income
- $-95,526,623-761.4%
- EPS
- $-22.58-10163.6%
- OCF Growth
- -177.7%
- FCF Growth
- -177.7%
- 52W High
- $12.80
- 52W Low
- $4.12
- 50D MA
- $10.39
- 200D MA
- $10.74
- Beta
- 0.04
- RSI (14)
- 30
- Avg Volume
- 8.08K
No earnings-call transcripts are available for PBAX yet.
- Free Float
- 15.1%
- Shares Outstanding
- 6.23M
- Float Shares
- 940.12K
of shares held by institutions
20 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Arena Investors LP | 198.57K | ▲ 198.57K |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 8, 21 | PHOENIX BIOTECH SPONSOR, LLC | other | 82,875 |
| Oct 8, 21 | PHOENIX BIOTECH SPONSOR, LLC | other | 36,733 |
| Oct 8, 21 | PHOENIX BIOTECH SPONSOR, LLC | other | 18,366 |
| Oct 8, 21 | Ehrlich Christopher B | other | 82,875 |
| Oct 8, 21 | Ehrlich Christopher B | other | 36,733 |
| Oct 8, 21 | Ehrlich Christopher B | other | 18,366 |
| Oct 8, 21 | Geffken Daniel E. | other | 30,000 |
| Oct 8, 21 | Loewy Caroline M | other | 17,500 |
| Oct 8, 21 | Fisher Douglas | other | 100,000 |
| Oct 8, 21 | Fisher Douglas | other | 10,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our PBAX coverage
Recent articles, reports, and earnings notes.
No research on PBAX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PBAX report →Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.